source
- Pfizer drops phase 2 pulmonary arterial hypertension candidate amid pipeline cutPfizer has discontinued its phase 2 pulmonary arterial hypertension (PAH) program, PF-07868489, citing business reasons rather than safety or efficacy concerns. The drug, which targets BMP9 inhibi…
- AbbVie commits £120 million to new Oxford R&D hub, boosting UK life‑science footprintAbbVie announced a £120 million ($160 million) investment to expand its research footprint in the United Kingdom. The company will open a new 12,000‑square‑foot R&D facility in Oxford, joining its…